Fast Facts: Bladder Cancer
Our understanding of the biology of bladder cancer has advanced remarkably since the second edition of 'Fast Facts: Bladder Cancer' was published in 2006. Five new immunotherapies targeting the PD-1 axis were approved in 2016 and 2017 for the treatment of advanced bladder cancer, reflectin...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Livre numérique |
| Kieli: | Anglais |
| Julkaistu: |
Basel :
S. Karger
2018.
Basel : |
| Painos: | 3rd edition. |
| Linkit: | https://www.karger.com/Book/Home/277616 Accès Université d'Orléans et IFPM |
| Huomautus: |
Karger Fast Facts |
| Autres localisations: | Voir dans le Sudoc |
| Edition sous un autre format: | • Fast Facts: Bladder Cancer, 9781910797648 |
| Yhteenveto: | Our understanding of the biology of bladder cancer has advanced remarkably since the second edition of 'Fast Facts: Bladder Cancer' was published in 2006. Five new immunotherapies targeting the PD-1 axis were approved in 2016 and 2017 for the treatment of advanced bladder cancer, reflecting this transformative explosion in knowledge about the biology of the disease. This new era of targeted treatment offers hope to patients, particularly those with advanced disease. However, for clinicians it means a lot to understand in terms of how these immunotherapies are integrated into the treatment paradigm. Who they are suitable for? When are they best used? What is the optimal sequence of treatments for individual patients? |
|---|---|
| Huomautukset: | Karger Fast Facts |
| ISBN: | 9781910797655 |
| Pääsy: | Accès libre pour tout établissement ou utilisateur ayant un compte sur la plateforme de l'éditeur |